Last reviewed · How we verify
LAF 237
LAF 237 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes.
LAF 237 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | LAF 237 |
|---|---|
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Drug class | DPP-4 inhibitor |
| Target | DPP-4 (Dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
LAF 237 works by inhibiting the enzyme dipeptidyl peptidase-4, which normally breaks down incretin hormones (GLP-1 and GIP). By preventing this degradation, the drug increases circulating levels of these hormones, which stimulate insulin secretion and reduce glucagon release in response to meals, thereby lowering blood glucose levels.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nasopharyngitis
- Headache
- Upper respiratory tract infection
Key clinical trials
- A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM (PHASE4)
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. (PHASE4)
- Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome (PHASE2, PHASE3)
- Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (PHASE2)
- Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors (PHASE4)
- Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia (PHASE2)
- The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients (PHASE1, PHASE2)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |